ReviewRheumatology advances in practice2023

Is symptom duration before DMARD therapy a determinant of direct and indirect costs in DMARD-naïve RA patients? A systematic review.

Ilfita Sahbudin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.